Affiliation:
1. From the Department of Physiology and Biophysics, Mayo School of Medicine and Division of Hypertension, Mayo Clinic (J.C.R.) Rochester, Minn; and the Department of Physiology and Biophysics and the Center for Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center (J.F.R.), Jackson, Miss.
Abstract
Abstract
—In this review, we examine the possibility that small increments in angiotensin II are responsible for an increase in blood pressure and maintenance of hypertension through the stimulation of oxidative stress. A low dose of angiotensin II (2 to 10 ng · kg
−1
· min
−1
, which does not elicit an immediate pressor response), when given for 7 to 30 days by continuous intravenous infusion, can increase mean arterial pressure by 30 to 40 mm Hg. This slow pressor response to angiotensin is accompanied by the stimulation of oxidative stress, as measured by a significant increase in levels of 8-iso-prostaglandin F
2α
(F
2
-isoprostane). Superoxide radicals and nitric oxide can combine chemically to form peroxynitrite, which can then oxidize arachidonic acid to form F
2
-isoprostanes. F
2
-isoprostanes exert potent vasoconstrictor and antinatriuretic effects. Furthermore, angiotensin II can stimulate endothelin production, which also has been shown to stimulate oxidative stress. In this way, a reduction in the concentration of nitric oxide (which is quenched by superoxide) along with the formation of F
2
-isoprostanes and endothelin could potentiate the vasoconstrictor effects of angiotensin II. We hypothesize that these mechanisms, which underlie the development of the slow pressor response to angiotensin II, also participate in the production of hypertension when circulating angiotensin II levels appear normal, as occurs in many cases of essential and renovascular hypertension.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference74 articles.
1. The Primary Role of the Kidney and Salt Intake in the Aetiology of Essential Hypertension: Part I
2. Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive Patients
3. Nelson EB Harm SC Goldberg M Shahinfar S Goldberg A Sweet CS. Clinical profile of the first angiotensin II (AT-1 specific) receptor antagonists. In: Laragh JH Brenner BM eds. Hypertension Pathophysiology Diagnosis and Management. 2nd ed. New York NY: Raven Press; 1995:2895–2916.
Cited by
302 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献